Loading organizations...
§ Private Profile · Recoleta, Distrito Federal, Argentina
Precision oncology company providing genomic testing and biomarker analysis for personalized cancer treatment, guiding targeted therapies.
Founded in 2014 by Nicolás Kirchuk and Rubén Salanova, Biomakers is a precision oncology company based in Buenos Aires and San Francisco that provides personalized cancer treatment guidance through the genomic analysis of tumor and liquid biopsies. The organization utilizes techniques such as next-generation sequencing and digital PCR to test biomarkers for lung, colorectal, breast, sarcoma, and central nervous system cancers. Serving healthcare providers, pharmaceutical companies, and research institutions, the company recently partnered with a LabCorp division to expand Latin American access to clinical trials. Biomakers has raised $11.4 million in total funding, including a recent $2.4 million Series A-II round backed by investors such as Sky High VC, Endurance28, and Sonen Capital. The firm monetizes genomic data across various drug development stages and reports adding over 9,000 years to cancer patients' lives since 2017.
Biomakers has raised $8.0M across 1 funding round.
Biomakers has raised $8.0M in total across 1 funding round.
Biomakers has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 15, 2026 | $8M Series A | — | Consuelo Valverde, Labcorp, BEN Freeberg, SKY High Fund, Sonen Capital, Zentynel Frontier Investments | Announced |
Biomakers has raised $8.0M in total across 1 funding round.
Biomakers's investors include Consuelo Valverde, Labcorp, Ben Freeberg, Sky High Fund, Sonen Capital, Zentynel Frontier Investments.